Alliance Pharma receives positive opinion for Diclectin
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.
Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.
Clinical study supports the use of Cheetah Medical's technologies
Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock
Vertos Medical Secures $28m in Latest Round of Funding
Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.
VitalConnect Announces Closure of $33m Series C Financing
VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.
Providence Medical Technology announces new equity financing of $10.5 million
Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.
Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease
Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.
MVM invests €15.2m in Valneva SE
Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera
MVM Life Science Partners LLP closes MVM IV
MVM Life Science Partners LLP announces the closing of a $233 million healthcare fund, MVM IV.
Heptares and Allergan Announce Global R&D and Commercialization Partnership
Heptares and Allergan Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders